It has been documented that those compounds with GSK3β inhibitory activity seem to be an effective pharmacological approach for treating AD as they reduced neuropathological hallmarks and alleviated cognitive dysfunction in the in vivo model of AD [50]. This evidence concerns the gene GSK3B and Alzheimer disease.